Former Perrigo Executive Wins Partial Dismissal of Generic-Drug Price-Fixing Claims

Douglas Boothe, a former executive vice president and general manager of a Perrigo business, won summary judgment on some of the claims against him in the U.S. District Court for the District of Connecticut, according to a Sept. 14 report by Bloomberg Law. The ruling was issued Sept. 11 by US District Judge Michael P. Shea.

We’d love to be your preferred source for news.

Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

Add as Preferred Source

The litigation alleges that Boothe conspired with pharmaceutical executives and companies over prices for generic skin-care and other pharmaceutical products. Shea concluded, however, that the plaintiffs had failed to produce evidence showing Boothe’s direct participation in an unlawful agreement involving certain drugs, according to Bloomberg Law.

Read more: Pfizer Wins Dismissal From Major Generic Drug Antitrust Case Brought by US States

Among the products covered by the claims that lacked sufficient evidence were adapalene cream and bromocriptine tablets, Bloomberg Law reported. The court’s decision means Boothe is still scheduled to go to trial, but only on the allegations that survived summary judgment.

Boothe previously served as an executive vice president and general manager for a Perrigo entity, according to the Bloomberg Law report, which cited his professional profile.

The Sept. 11 decision represents a partial victory for Boothe rather than a complete dismissal of the litigation. By eliminating claims for which the court found insufficient evidence of his direct involvement, the ruling reduces the scope of the allegations that plaintiffs can pursue against him at trial.

Source: Bloomberg Law